Back to Search Start Over

The Chemotype of Chromanones as a Privileged Scaffold for Multineurotarget Anti-Alzheimer Agents

Authors :
Keuler, T.
Lemke, C.
Elsinghorst, P. W.
Iriepa, I.
Chioua, M.
Martínez-Grau, M. A.
Beadle, C. D.
Vetman, T.
López-Muñoz, F.
Wille, T.
Bartz, U.
(0000-0003-3168-3062) Deuther-Conrad, W.
(0000-0003-0690-0328) Marco-Contelles, J.
(0000-0002-9376-7897) Gütschow, M.
Keuler, T.
Lemke, C.
Elsinghorst, P. W.
Iriepa, I.
Chioua, M.
Martínez-Grau, M. A.
Beadle, C. D.
Vetman, T.
López-Muñoz, F.
Wille, T.
Bartz, U.
(0000-0003-3168-3062) Deuther-Conrad, W.
(0000-0003-0690-0328) Marco-Contelles, J.
(0000-0002-9376-7897) Gütschow, M.
Source :
ACS Pharmacology & Translational Science 5(2022)11, 1097-1108
Publication Year :
2022

Abstract

The multifactorial nature of Alzheimer’s disease necessitates the development of agents able to interfere with different relevant targets. A series of 22 tailored chromanones was conceptualized, synthesized and subjected to biological evaluation. We identified one representative bearing a linker-connected azepane moiety (compound 19) with balanced pharmacological properties. Compound 19 exhibited inhibitory activities against human acetyl-, butyrylcholinesterase and monoamine oxidase-B, as well as high affinity to both the 1 and 2 receptor. Our study provides a framework for the development of further chromanone-based multineurotarget agents.

Details

Database :
OAIster
Journal :
ACS Pharmacology & Translational Science 5(2022)11, 1097-1108
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1415626450
Document Type :
Electronic Resource